APA (7th ed.) Citation

Gavrilova, I., Weichenthal, M., Asher, N., Ulrich, J., Ellebaek, E., Kreuter, A., . . . Schadendorf, D. (2025). 1642P The role of BRAF/MEKi rechallenge in BRAFV600 mutated melanoma patients: Insights from a EUMelaReg real-world study. Annals of Oncology, 36, S974. https://doi.org/10.1016/j.annonc.2025.08.2270

Chicago Style (17th ed.) Citation

Gavrilova, I., et al. "1642P The Role of BRAF/MEKi Rechallenge in BRAFV600 Mutated Melanoma Patients: Insights from a EUMelaReg Real-world Study." Annals of Oncology 36 (2025): S974. https://doi.org/10.1016/j.annonc.2025.08.2270.

MLA (9th ed.) Citation

Gavrilova, I., et al. "1642P The Role of BRAF/MEKi Rechallenge in BRAFV600 Mutated Melanoma Patients: Insights from a EUMelaReg Real-world Study." Annals of Oncology, vol. 36, 2025, p. S974, https://doi.org/10.1016/j.annonc.2025.08.2270.